行情

ALNY

ALNY

阿里拉姆制药
NASDAQ

实时行情|Nasdaq Last Sale

166.36
+1.29
+0.78%
盘后: 165.00 -1.36 -0.82% 17:18 01/15 EST
开盘
165.35
昨收
165.07
最高
171.01
最低
165.35
成交量
71.16万
成交额
--
52周最高
175.41
52周最低
84.97
市值
193.28亿
市盈率(TTM)
-21.2449
分时
5日
1月
3月
1年
5年
新闻
财报
公告
公司事件
分析
简况
每日生物技术脉动:Alexion暂停COVID-19研究,NantKwest读数,器官发生在指导下跳跃,试验更新
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 13)
Benzinga · 4天前
Vir Biotech, Glaxo to Begin Study on Second COVID-19 Therapy
Zacks.com · 5天前
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of ...
benzinga.com · 6天前
2020年创新药获批最大赢家:诺华(NVS.US)
医药魔方 · 01/07 00:21
生物技术日报:诺华获得Adcom的支持,Sio基因数据,两次IPO,BioNTech紧扣中国疫苗供应交易
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 15)
Benzinga · 2020/12/16 12:15
黑石集团以34.5亿美元的实验室交易显示生命科学蓬勃发展
The firm will be the largest life-sciences office owner in Cambridge, Mass.
Barrons.com · 2020/12/14 20:51
Orsini Specialty Pharmacy Expands Partnership With Alnylam Pharmaceuticals As A Limited Distribution Partner For OXLUMO
Orsini Specialty Pharmacy Expands Partnership With Alnylam® Pharmaceuticals As A Limited Distribution Partner For OXLUMO™ (lumasiran) ELK GROVE VILLAGE, Ill., Dec. 3, 2020 /PRNewswire/ -- Orsini
Benzinga · 2020/12/03 13:20
Alnylam Completes Enrollment In ILLUMINATE-C Phase 3 Study Of Lumasiran, An RNAi Therapeutic, For Treatment Of Advanced Primary Hyperoxaluria Type 1
- Topline Results Expected in Mid-2021 - Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it has achieved full patient enrollment in its ILLUMINATE-C Phase 3
Topline Results Expected in Mid-2021 - Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it has achieved full patient enrollment in its ILLUMINATE-C Phase 3 · 2020/12/03 13:01
更多
财务预测
每股收益每股净资产每股现金流
实际值(美元)
预测值(美元)
利润表更多
净利润营业总收入营业利润
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流投资现金流筹资现金流
经营现金流(美元)
同比(%)
了解ALNY最新的财务预测,通过ALNY每股收益,每股净资产,每股现金流等数据分析阿里拉姆制药近期的经营情况,然后做出明智的投资选择。
分析师评级

23位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测ALNY价格均价为166.00,最高价位225.00,最低价为90.00。
EPS
机构持股
总机构数: 515
机构持股: 1.15亿
持股比例: 98.81%
总股本: 1.16亿
类型机构数股数
增持
121
221.98万
建仓
80
-38.81万
减持
128
509.33万
平仓
0
0
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-0.34%
制药与医学研究
+0.21%
高管信息
Chairman/Director
Michael Bonney
President/Chief Operating Officer
Yvonne Greenstreet
Chief Executive Officer/Director
John Maraganore
Chief Financial Officer/Executive Vice President
Jeffrey Poulton
Corporate Executive
Akshay Vaishnaw
Chief Human Resource Officer/Senior Vice President
Kelley Boucher
Executive Vice President/Secretary
Laurie Keating
Senior Vice President/Chief Scientific Officer
Kevin Fitzgerald
Senior Vice President
Salil Patel
Other
Agnieszka Gallagher
Other
Tolga Tanguler
Director
Olivier Brandicourt
Independent Director
Dennis Ausiello
Independent Director
Marsha Fanucci
Independent Director
Margaret Hamburg
Independent Director
Steven Paul
Independent Director
David Pyott
Independent Director
Colleen Reitan
Independent Director
Amy Schulman
Independent Director
Phillip Sharp
  • 分红
  • 拆股
  • 内部人交易
暂无数据
注册即可获得3个月
免费美股Level2深度行情
(Nasdaq Totalview)
立即领取
ALNY 简况
Alnylam Pharmaceuticals Inc是一家生物制药公司。该公司从事核糖核酸(RNA)干扰(RNAi)治疗剂的发现、开发和商业化。该公司专注于使用其N-乙酰半乳糖胺(GalNAc)共轭平台来递送小干扰RNA(siRNA)。其研究性RNAi治疗药物的研发重点集中在三个战略治疗领域(STArs):遗传药物,具有多种治疗罕见病的候选药物;心血管疾病,其候选产品针对经过遗传验证的、肝表达的疾病靶标以满足未满足的心血管疾病和代谢疾病的需求;以及肝感染性疾病,其候选产品旨在解决从肝炎开始的肝感染性疾病的全球健康挑战乙型和丁型肝炎病毒感染。
展开
热门股票
代码
价格
涨跌幅

微牛提供Alnylam Pharmaceuticals, Inc.(NASDAQ-ALNY)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的ALNY股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ALNY股票基本功能。